JP2019502722A5 - - Google Patents

Download PDF

Info

Publication number
JP2019502722A5
JP2019502722A5 JP2018537761A JP2018537761A JP2019502722A5 JP 2019502722 A5 JP2019502722 A5 JP 2019502722A5 JP 2018537761 A JP2018537761 A JP 2018537761A JP 2018537761 A JP2018537761 A JP 2018537761A JP 2019502722 A5 JP2019502722 A5 JP 2019502722A5
Authority
JP
Japan
Prior art keywords
cells
immune
cell
population
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018537761A
Other languages
English (en)
Japanese (ja)
Other versions
JP7616817B2 (ja
JP2019502722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/014408 external-priority patent/WO2017127729A1/en
Publication of JP2019502722A publication Critical patent/JP2019502722A/ja
Publication of JP2019502722A5 publication Critical patent/JP2019502722A5/ja
Priority to JP2022010113A priority Critical patent/JP2022058761A/ja
Priority to JP2024053449A priority patent/JP2024081737A/ja
Application granted granted Critical
Publication of JP7616817B2 publication Critical patent/JP7616817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018537761A 2016-01-20 2017-01-20 養子免疫療法における免疫細胞調節のための組成物および方法 Active JP7616817B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022010113A JP2022058761A (ja) 2016-01-20 2022-01-26 養子免疫療法における免疫細胞調節のための組成物および方法
JP2024053449A JP2024081737A (ja) 2016-01-20 2024-03-28 養子免疫療法における免疫細胞調節のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662281064P 2016-01-20 2016-01-20
US62/281,064 2016-01-20
US201662336339P 2016-05-13 2016-05-13
US62/336,339 2016-05-13
PCT/US2017/014408 WO2017127729A1 (en) 2016-01-20 2017-01-20 Compositions and methods for immune cell modulation in adoptive immunotherapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010113A Division JP2022058761A (ja) 2016-01-20 2022-01-26 養子免疫療法における免疫細胞調節のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019502722A JP2019502722A (ja) 2019-01-31
JP2019502722A5 true JP2019502722A5 (cg-RX-API-DMAC10.html) 2020-02-27
JP7616817B2 JP7616817B2 (ja) 2025-01-17

Family

ID=59362673

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018537761A Active JP7616817B2 (ja) 2016-01-20 2017-01-20 養子免疫療法における免疫細胞調節のための組成物および方法
JP2022010113A Pending JP2022058761A (ja) 2016-01-20 2022-01-26 養子免疫療法における免疫細胞調節のための組成物および方法
JP2024053449A Pending JP2024081737A (ja) 2016-01-20 2024-03-28 養子免疫療法における免疫細胞調節のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022010113A Pending JP2022058761A (ja) 2016-01-20 2022-01-26 養子免疫療法における免疫細胞調節のための組成物および方法
JP2024053449A Pending JP2024081737A (ja) 2016-01-20 2024-03-28 養子免疫療法における免疫細胞調節のための組成物および方法

Country Status (9)

Country Link
US (3) US11096964B2 (cg-RX-API-DMAC10.html)
EP (1) EP3405567A4 (cg-RX-API-DMAC10.html)
JP (3) JP7616817B2 (cg-RX-API-DMAC10.html)
KR (1) KR102878032B1 (cg-RX-API-DMAC10.html)
CN (2) CN116376826A (cg-RX-API-DMAC10.html)
AU (3) AU2017210031C1 (cg-RX-API-DMAC10.html)
CA (1) CA3010236A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201805186VA (cg-RX-API-DMAC10.html)
WO (1) WO2017127729A1 (cg-RX-API-DMAC10.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
CN118662615A (zh) * 2017-03-15 2024-09-20 浩康生物系统公司 用于造血干细胞移植的组合物和方法
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
US20200289566A1 (en) * 2017-11-20 2020-09-17 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions for improving car-t cell functionality and use thereof
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
KR20200119840A (ko) * 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
KR20210016511A (ko) * 2018-05-31 2021-02-16 크리티테크, 인크. 입양 세포 요법 및 암 백신을 위한 종양 특이적 면역 세포를 대상체로부터 단리하는 방법
US20200040056A1 (en) * 2018-05-31 2020-02-06 Washington University Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN109136276A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种rfft2细胞的构建方法
US11596692B1 (en) * 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
JP2022510207A (ja) * 2018-12-02 2022-01-26 フェイト セラピューティクス,インコーポレイテッド 増強されたiPSC派生エフェクター細胞を使用した免疫療法
CN113365654A (zh) * 2019-01-29 2021-09-07 Gpb科学有限公司 具有改进的生产和治疗特征的细胞群
BR112021016046A2 (pt) * 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したnk細胞画分の増殖及び増殖nk細胞画分の使用
KR20200122261A (ko) 2019-04-17 2020-10-27 (주)차바이오텍 항암 활성이 증가된 자연살해세포 및 그의 면역 치료 용도
KR102300846B1 (ko) * 2019-11-01 2021-09-09 서울대학교산학협력단 면역 활성 개선용 조성물 및 이의 방법
JP7842690B2 (ja) 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
TWI784426B (zh) * 2020-03-02 2022-11-21 中央研究院 自然殺手細胞的放大方法
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
CN114746152A (zh) 2020-08-23 2022-07-12 应用干细胞有限公司 Hla-f修饰的细胞和方法
EP4232567A1 (en) * 2020-10-26 2023-08-30 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
US20240150711A1 (en) * 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用
US20240366806A1 (en) * 2021-07-02 2024-11-07 Case Western Reserve University Adoptive immunotherapy compositions and methods of tracking
CN116716342A (zh) * 2022-06-22 2023-09-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
CN115997726B (zh) * 2022-07-11 2024-11-22 济宁医学院附属医院 一种靶向脊髓前角运动神经元ampk的aman小鼠模型构建方法
EP4604966A1 (en) * 2022-10-20 2025-08-27 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
WO2024084518A1 (en) * 2022-10-20 2024-04-25 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
CN117316291B (zh) * 2023-10-20 2024-08-09 南方医科大学南方医院 基于免疫治疗疗效与毒性关系的免疫调节基因分类方法
CN118272305B (zh) * 2024-04-29 2025-04-08 深圳泽医细胞治疗集团有限公司 一种免疫细胞的培养基及其应用
CN118325837B (zh) * 2024-06-12 2024-09-03 深圳市中佳生物医疗科技有限公司 中性粒细胞的无血清无基质细胞培养方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003455C (en) 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
HK1048302A1 (zh) 1999-08-13 2003-03-28 大正制药株式会社 前列腺素衍生物
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20040175373A1 (en) 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
WO2007103901A2 (en) * 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
GB2444853B (en) * 2006-12-14 2010-02-24 Medical Res Council Methods & uses
JP5951254B2 (ja) * 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
AU2009322346B2 (en) 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
EP2375897A4 (en) * 2009-01-14 2013-05-15 Health Research Inc METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
JP5897035B2 (ja) * 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド,ボルチモア 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CA2977839C (en) * 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
WO2015155738A2 (en) * 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
RS61406B1 (sr) * 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CA2980592A1 (en) 2015-03-27 2016-10-06 Nantkwest, Inc. Nk-92 cells in combination therapy with cancer drugs
HK1247958A1 (zh) 2015-05-05 2018-10-05 菲特治疗公司 T淋巴细胞的调节
CN107849102B (zh) 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
WO2017040324A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3638775A1 (en) 2017-06-13 2020-04-22 Fate Therapeutics, Inc. Compositions and methods for inducing myeloid suppressive cells and use thereof
CN111511762B (zh) * 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途

Similar Documents

Publication Publication Date Title
JP2020528885A5 (cg-RX-API-DMAC10.html)
JP2019502725A5 (cg-RX-API-DMAC10.html)
US12036241B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7616817B2 (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
JP7664913B2 (ja) 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用
JP2025038093A (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
JP7747352B2 (ja) 操作されたガンマデルタt細胞ならびにその作製方法および使用方法
IL293564A (en) Enhancement of an effector immune cell, derived from an induced pluripotent stem cell, using small molecules
US20240358760A1 (en) Primary T-Cell Expansion
US20140037599A1 (en) Compositions and Methods of Treating T Cell Deficiency
KR20180063847A (ko) 멀티플렉스 CRISPR-Cas9 시스템을 이용한 HLA 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도
US20250368955A1 (en) B cell lineages derived from pluripotent cells
WO2024220222A1 (en) Media and methods for differentiating t cells from hematopoietic stem cells
Yazdanparast et al. CAR-NK cell therapy in multiple myeloma: From preclinical and clinical landscape to joining the force for treatment strategies optimization
CN119452076A (zh) 免疫细胞的产生
CN117979978A (zh) 从干细胞产生经工程化的t细胞
CN117940139A (zh) 对用于同种异体car t细胞疗法的干细胞进行工程化
US20260071180A1 (en) Genetically engineered placental mucosalassociated invariant t (mait) cells and uses thereof
HK40119436A (en) Genetically engineered placental mucosal-associated invariant t (mait) cells and uses thereof
Kögler et al. Biology of umbilical cord blood cells
Melenhorst et al. Tumor vaccines and beyond
CN121896164A (zh) 一种t细胞培养基、细胞培养物及其培养方法和应用
JP2024542151A (ja) Nk細胞の生成法
WO2025125443A1 (en) Production of immune cells
CN120303393A (zh) 多能干细胞来源的t细胞群体及其祖细胞